Christina Annunziata
#95,199
Most Influential Person Now
American medical oncologist
Christina Annunziata's AcademicInfluence.com Rankings
Christina Annunziatamedical Degrees
Medical
#1566
World Rank
#1918
Historical Rank
Oncology
#273
World Rank
#282
Historical Rank
Christina Annunziataphilosophy Degrees
Philosophy
#11644
World Rank
#16076
Historical Rank
Logic
#8453
World Rank
#10579
Historical Rank
Download Badge
Medical Philosophy
Christina Annunziata's Degrees
- Bachelors Biology Duke University
Similar Degrees You Can Earn
Why Is Christina Annunziata Influential?
(Suggest an Edit or Addition)According to Wikipedia, Christina Messineo Annunziata is an American medical oncologist researching molecular signal transduction in ovarian cancer. She is an investigator in the National Cancer Institute's women's malignancies branch and head of the translational genomics section.
Christina Annunziata's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. (2007) (976)
- Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. (2008) (322)
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial (2019) (257)
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. (2017) (182)
- Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. (2014) (171)
- Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression (2018) (164)
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. (2020) (155)
- Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer (2010) (150)
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study (2018) (133)
- Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors (2018) (123)
- Reed-Sternberg cell genome expression supports a B-cell lineage. (1999) (118)
- Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. (2010) (114)
- The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. (2010) (106)
- Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer (2010) (98)
- Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition (2008) (95)
- Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. (2020) (95)
- Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study (2020) (86)
- Proteomics in Clinical Trials and Practice (2006) (82)
- Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors (2012) (79)
- Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. (2016) (77)
- Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 (2010) (77)
- Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer (2016) (76)
- Rapid image deconvolution and multiview fusion for optical microscopy (2020) (73)
- A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. (2011) (72)
- Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment (2016) (71)
- A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses (2019) (69)
- Proteasome inhibitors: structure and function. (2017) (67)
- Voltage-gated Na+ Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling (2015) (65)
- NF-κB Signaling in Ovarian Cancer (2019) (60)
- Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity (2010) (60)
- Hodgkin disease: pharmacologic intervention of the CD40-NFκB pathway by a protease inhibitor (2000) (55)
- Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions (2013) (54)
- Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells (2012) (53)
- SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2. (2016) (53)
- NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells. (2017) (53)
- Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells (2015) (50)
- Proteomics as a Tool for Biomarker Discovery (2007) (47)
- Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. (2006) (47)
- SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors (2017) (42)
- BAG-4/SODD and Associated Antiapoptotic Proteins Are Linked to Aggressiveness of Epithelial Ovarian Cancer (2007) (42)
- The role of reproductive hormones in epithelial ovarian carcinogenesis. (2015) (39)
- Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer (2016) (39)
- Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer (2014) (37)
- Lack of reliability of CA125 response criteria with anti‐VEGF molecularly targeted therapy (2008) (36)
- IKK-ε coordinates invasion and metastasis of ovarian cancer. (2012) (36)
- Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome (2016) (32)
- PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer (2010) (31)
- A dual role for Caspase8 and NF-κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival (2015) (31)
- A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma (2015) (31)
- SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). (2013) (30)
- Feasibility and safety of sequential research‐related tumor core biopsies in clinical trials (2013) (28)
- In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells (2015) (28)
- Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers. (2018) (28)
- A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa). (2018) (28)
- Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca). (2011) (27)
- Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results (2007) (27)
- A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. (2013) (26)
- Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor. (2000) (25)
- Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404). (2016) (25)
- Monocyte and interferon based therapy for the treatment of ovarian cancer. (2016) (24)
- Caspase 8 expression may determine the survival of women with ovarian cancer (2016) (22)
- PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma (2017) (22)
- Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome (2012) (21)
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline Summary. (2020) (21)
- IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts (2018) (21)
- Activation of NF- κ B Signaling by Inhibitor of NF- κ B Kinase β Increases Aggressiveness of Ovarian Cancer (2010) (18)
- An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells (2019) (18)
- Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer (2017) (18)
- Pathway-Specific Engineered Mouse Allograft Models Functionally Recapitulate Human Serous Epithelial Ovarian Cancer (2014) (17)
- Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas (2018) (17)
- Ovarian cancer in the proteomics era (2008) (17)
- A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer (2018) (17)
- A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa) (2016) (16)
- Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. (2017) (15)
- Driving Immune Responses in the Ovarian Tumor Microenvironment (2021) (15)
- Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model (2020) (14)
- Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk (2019) (13)
- BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). (2017) (13)
- Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug—induced DNA double strand breaks from DNA double strand breaks associated with apoptosis (2018) (13)
- Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. (2020) (13)
- Translational Predictive Biomarker Analysis of the Phase 1b Sorafenib and Bevacizumab Study Expansion Cohort* (2013) (13)
- Accelerating iterative deconvolution and multiview fusion by orders of magnitude (2019) (12)
- A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients. (2011) (12)
- The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes. (2020) (12)
- Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21 (2014) (12)
- Targeting the Proteasome With Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit as an Upfront Single Agent, Induction Regimen for Stem-Cell Transplantation and as Maintenance Therapy (2012) (12)
- Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use (2019) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors (2017) (10)
- BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1) (2017) (10)
- Are beta‐blockers on the therapeutic horizon for ovarian cancer treatment? (2015) (8)
- Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women’s cancers (2017) (8)
- Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target (2018) (8)
- Novel facts about FAK: new connections to drug resistance? (2013) (8)
- Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas (2017) (8)
- Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study. (2020) (7)
- The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. (2020) (7)
- Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062). (2013) (7)
- Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age (2013) (7)
- Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer (2020) (6)
- A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. (2015) (6)
- The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells (2014) (6)
- Identification of therapeutic targets applicable to clinical strategies in ovarian cancer (2016) (6)
- A phase II study of intermittent sorafenib with bevacizumab (B) in B-naive and prior B-exposed epithelial ovarian cancer (EOC) patients. (2014) (6)
- Is there a genomic basis for primary chemoresistance in ovarian cancer? (2003) (6)
- Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course. (2019) (5)
- Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells (2022) (5)
- Correlative studies of a phase I trial of combination anti-vascular endothelial growth factor (VEGF) therapy with sorafenib and bevacizumab (2008) (5)
- NFkB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDHþ Cancer Stem–like Cells (2017) (4)
- Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas (2022) (4)
- Clinical trials in gynecologic oncology: Past, present, and future. (2017) (4)
- Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368). (2014) (4)
- Abstract 3821: The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitory CEACAM5/CEACAM1 immune checkpoint pathway (2018) (3)
- Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418). (2015) (3)
- The clinical trials crisis in gynecologic oncology. (2017) (3)
- Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. (2020) (3)
- Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis (2022) (3)
- Translational proof of mechanism (PoM) for sorafenib with bevacizumab: Endpoint analysis and clinical activity. (2009) (3)
- Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism (2021) (3)
- Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers (2020) (3)
- Abstract 3025: Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies (2017) (3)
- A Phase II Trial of AZD 6244 ( Selumetinib , ARRY-142886 ) , an Oral MEK 1 / 2 Inhibitor , in Relapsed / Refractory Multiple Myeloma (2015) (3)
- Intraperitoneal monocytes and interferons as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results of a phase I clinical trial. (2022) (3)
- Phase I with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors. (2019) (2)
- Prenatal DNA Sequencing for Fetal Aneuploidy Also Detects Maternal Cancer: Importance of Timely Workup and Management in Pregnant Women. (2022) (2)
- Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer (2020) (2)
- Abstract CT326: Pharmacokinetic/pharmacodynamic study of sequence specificity of the PARP inhibitor, olaparib and carboplatin in recurrent women's cancers (2015) (2)
- 390PA phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women’s cancers (2017) (2)
- Novel Strategies in the Treatment of Multiple Myeloma: From Proteasome Inhibitors to Immunotherapy (2010) (2)
- Editorial: Inhibiting PARP as a Strategic Target in Cancer (2016) (2)
- 840 A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression (2021) (2)
- Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors. (2010) (2)
- CD157 in ovarian carcinoma: how does it help us? (2010) (2)
- Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. (2020) (2)
- PARP inhibitors in BRCA 1 / BRCA 2 germline mutation carriers with ovarian and breast cancer (2010) (2)
- Abstract 3821: Targeted therapy for head and neck squamous cell carcinoma using the novel SMAC-mimetic birinapant (2016) (2)
- The Expanding Role of Proteasome-Based Therapy in the Treatment of Hematologic Malignancies (2010) (2)
- A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC) (2016) (2)
- Abstract 167: Targeting the NF-kappaB pathway with bardoxolone methyl to inhibit ovarian cancer spheroid formation (2018) (1)
- Phase 1 study of intraperitoneal infusion of autologous monocytes with peginterferon alfa-2b and interferon gamma-1b in women with recurrent or refractory ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. (2017) (1)
- First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (2023) (1)
- Uterine papillary serous carcinoma (2009) (1)
- IAP antagonism enhances anti-tumor activity of docetaxel or panobinostat in ovarian cancer cell lines (2018) (1)
- A New Paradigm for Treatment (2009) (1)
- Abstract OT2-07-04: A phase 2 study of ONC201 in recurrent/refractory metastatic breast cancer and advanced endometrial carcinoma (2018) (1)
- Effect of metformin chemoprevention on metabolomics profiles in Li-Fraumeni Syndrome (LFS). (2017) (1)
- Abstract 1188: BRCA 1/2 mutation status is correlated with increased hypersensitivity reactions to carboplatin. (2013) (1)
- Abstract CT337: Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in triple negative breast cancer (TNBC) at low genetic risk (NCT00647062) (2014) (1)
- Abstract 278: No cell left behind: Residual ovarian spheroids drive recurrence and are sensitive to the pro-oxidant elesclomol (2016) (1)
- Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201 (2022) (1)
- Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors (2008) (1)
- 637 Phase IIa combining NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors (2022) (1)
- Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study (2011) (1)
- Inhibiting PARP as a Strategic Target in Cancer (2016) (1)
- Oncology patient and practitioner experience with complementary/alternative medicine at the NIH Clinical Center. (2018) (1)
- Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT+) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062) (2013) (1)
- Potential Synergy of TRAIL with CDK9 Inhibition in Selective Killing of HIV Infected Cell Lines and Primary CD4+ T Cells (2014) (1)
- Correlation of clinical activity of NEO201 mAb with the expression of NK activation markers and levels of soluble factors. (2020) (1)
- First-in-human phase I study of intraperitoneally administered interferon-activated autologous monocytes in platinum-resistant or refractory ovarian cancer. (2020) (1)
- 97 Birinapant, a Novel Smac Mimetic, Activates Apoptosis in NF-kappaB-dependent Gynecologic Cancer Cell Lines (2012) (0)
- Abstract 4534: A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can enhance NK activity and target immunosuppressive regulatory T cells (2020) (0)
- Response: Re: CD157 in Ovarian Carcinoma: How Does It Help Us? (2010) (0)
- Abstract 3582: Drugs targeting ovarian cancer tumor-initiating cells enhance oxidative stress and prevent disease recurrence (2020) (0)
- Identification of therapeutic targets applicable to clinical strategies in ovarian cancer (2016) (0)
- Abstract 1496: Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes (2016) (0)
- Abstract 3781: NF-κB classical and alternative signaling differentially regulate miRNA expression in ovarian cancer (2023) (0)
- Thank you to all of our reviewers in 2020 (2021) (0)
- blockade of MAF oncogene expression A mechanistic rationale for MEK inhibitor therapy in myeloma based on (2011) (0)
- Abstract 5820: NF-κB signaling regulates miRNA expression in ovarian cancer (2022) (0)
- Clinical Trials in Gynecologic Oncology: Past, Present, and Future (2018) (0)
- Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism (2021) (0)
- The survival advantage of adjuvant chemoradiotherapy in surgically managed patients with FIGO stages I-III uterine carcinosarcoma treated in Commission on Cancer®-accredited facilities (2020) (0)
- 363 Cytosolic p21 is a pharmacodynamic marker of CHEK1 and IKK inhibition in ovarian cancer cells (2014) (0)
- Abstract 4794: Mitochondrial matrix protease ClpP agonists inhibit cell growth and cancer stem cell function in breast cancer cells (2020) (0)
- Improving the clinical performance of blood-based DNA methylation biomarkers utilizing locus-specific epigenetic heterogeneity (2019) (0)
- Abstract 3144: shRNA library screening by dual shRNA technique identifies CHEK1 as a synthetic lethal gene in the absence of IKKε in ovarian cancer. (2013) (0)
- Upregulation of the extrinsic apoptosis pathway by docetaxel, panobinostat, and volasertib may potentiate synergy with birinapant in high-grade serous ovarian cancer (2016) (0)
- SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling (2023) (0)
- Abstract C158: IKKβ inhibition modulates NF‐κB signaling and decreases aggressiveness of ovarian cancer (2009) (0)
- Abstract 5179: Context-specific dependence of ovarian cancer on IKKε and CHEK1 (2014) (0)
- Another wrinkle with age: Aged collagen and intra‐peritoneal metastasis of ovarian cancer (2022) (0)
- Thanks to authors and peer reviewers (2008) (0)
- Abstract 1011: Disulfiram superior to ALDH1A1 inhibitor analogs in targeting ovarian cancer stem cells (2021) (0)
- Abstract CT159: A phase 1 study of intraperitoneal MCY-M11 therapy for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy (2019) (0)
- Abstract P127: Mitochondrial matrix protease ClpP agonists suppress breast cancer stem cell function by downregulating multiple stem cell regulatory mechanisms (2021) (0)
- Abstract 3577: First-in-human phase I study of intraperitoneally administered interferon-activated autologous monocytes in platinum-resistant ovarian cancer (2022) (0)
- Abstract 1923: NF-κB signaling supports a sub-population of ovarian cancer tumor-initiating cells (2014) (0)
- Abstract POSTER-THER-1422: Development of proteomic biomarkers for the apoptosis pathway in ovarian cancer cell lines and determination of the appropriate sequence of the SMAC-mimetic birinapant (TL32711) and docetaxel for optimal therapeutic effect (2015) (0)
- A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer (2018) (0)
- Abstract 2043: Effects of 24-h carboplatin pretreatment on olaparib clearance in women's cancers using noncompartmental and population pharmacokinetic analyses (2016) (0)
- associated with adverse patient outcome The sumoylation pathway is dysregulated in multiple myeloma and is (2014) (0)
- Abstract 1910: NF-kappaB classical versus alternative pathways support distinct populations of ovarian cancer tumor-initiating cells (2017) (0)
- MEK inhibition is selectively toxic to the genetically defined poor prognosis subset of multiple myeloma overexpressing the c-maf oncogene (2008) (0)
- IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts (2018) (0)
- The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells (2014) (0)
- Abstract LB-254: High-throughput drug matrix screen with SMAC (second mitochondria-derived activator of caspases)-mimetic birinapant in high-grade serous ovarian cancer cell lines identifies synergism (2015) (0)
- Abstract 4688: HPV+ cervical cancer cells are selectively killed by the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and the cyclin-dependent kinase-9 inhibitor (CDK9i) dinaciclib (2016) (0)
- 392 Genome-wide shRNa Library Screen Identifies CASPASE 8 as a Gene Sensitizing Ovarian Cancer Cells to IKKβ Inhibition (2012) (0)
- Abstract POSTER-TECH-1102: Caspase 8 cooperates with IKKβ to protect ovarian cancer cells from necroptosis (2015) (0)
- Abstract 3315: Activating innate immune response as strategy for endometrial cancer treatment (2020) (0)
- Radiation Therapy for Cervical Cancer : An 3 ASTRO Clinical Practice Guideline (2019) (0)
- A phase I dose expansion cohort study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509). (2017) (0)
- Abstract 35: Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509). (2013) (0)
- Abstract CT113: A phase II study of prexasertib, a cell cycle checkpoint kinase 1 (CHK1) inhibitor, in platinum-resistant recurrent high-grade serous ovarian cancer (HGSOC) with BRCA wild-type (BRCAwt) (2022) (0)
- Abstract AP26: SMAC–MIMETIC TREATMENT ENHANCES ANTITUMOR EFFECT OF STANDARD CHEMOTHERAPY IN OVARIAN CANCERS EXPRESSING LOW CASPASE 8 IN VITRO AND IN VIVO (2017) (0)
- Abstract 2007: The NF-kB pathway is constitutively active in endometrial cancer. (2013) (0)
- Abstract 1479: IKK-epsilon contributes to the malignant progression of ovarian cancer (2011) (0)
- Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression (2018) (0)
- Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (2023) (0)
- Abstract 3490: Topotecan synergizes with CHEK1 inhibitor to induce apoptosis in ovarian cancer cells (2015) (0)
- Abstract 3188: Modulating UGDH expression in ovarian cancer tumor-initiating cells alters the tumor microenvironment (2022) (0)
- Production of autologous monocytes stimulated ex vivo with peg-interferon alfa 2b and interferon gamma 1b for intraperitoneal administration in phase I clinical trial. (2019) (0)
- Abstract 1955: IKKε maintains MEK activation and suppresses non-canonical NF-κB signaling in triple-negative breast cancer (2015) (0)
- Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies. (2012) (0)
- Abstract 3947: Mechanisms of action of a neoantigen-targeting antibody NEO-201 (2019) (0)
- Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers (2020) (0)
- Abstract 5470: IKK-epsilon supports anchorage independent growth via alternative NF-kB signaling in triple-negative breast cancer (2018) (0)
- High-throughput matrix screening in ovarian cancer cells identifies synergistic drug combinations with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant (TL32711) (2015) (0)
- Flotillin-2 regulates EGFR activation, degradation, and cancer growth (2022) (0)
- ’ s response to reviews Title : Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE 1 and RB 1 genes (2019) (0)
- UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer (2022) (0)
- Rapid image deconvolution and multiview fusion for optical microscopy (2020) (0)
- Abstract B25: An unbiased functional screen identifies kinases essential to ovarian cancer cell survival (2013) (0)
- Abstract 112: Identifying drugs that target ovarian cancer tumor initiating cells (2017) (0)
- Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells (2015) (0)
- Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors. (2019) (0)
- Cytokine & Growth Factor Reviews (2016) (0)
- Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κ B 2 Signaling for Cancer Treatment 3 4 (2016) (0)
- Referee Acknowledgement for 2016 (2017) (0)
- Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use (2019) (0)
- Referee acknowledgement for 2017 (2018) (0)
- Effect of the combination of tumor necrosis factor related apoptosis inducing ligand (TRAIL) and the cyclin dependent kinase inhibitor dinaciclib on HPV+ cervical cancer cells. (2016) (0)
- Abstract TMIM-073: THE COMBINATION OF INTERFERONS ALPHA AND GAMMA AND MONOCYTES INDUCES OVARIAN CANCER CELL DEATH AND PROVIDE A RATIONALE FOR A NOVEL, ONGOING, IMMUNOTHERAPY PHASE 1 CLINICAL TRIAL (2019) (0)
- 405 A non-canonical role for CCL2 in T cell migration: improving dual-interferon-treated autologous monocytes as a therapy for ovarian cancer (2022) (0)
- A phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy (2019) (0)
- Indirect mechanisms of action of a novel IgG1 monoclonal antibody, NEO-201, to enhance immune killing of tumor. (2020) (0)
- Abstract A72: Dissecting the role of NF-kappaB signaling in ovarian cancer tumor-initiating cells. (2016) (0)
- Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes (2016) (0)
- 534 CHEK1 Cooperates with IKKe to Promote Survival of Ovarian Cancer Patients (2012) (0)
- BAG-4 / SODDand Associated Antiapoptotic Proteins Are Linked to Aggressiveness of Epithelial Ovarian Cancer (2007) (0)
- Interferons alpha and gamma with monocytes as a therapeutic strategy for ovarian cancer. (2020) (0)
- Abstract CT156: Safety and tolerability of metformin for chemoprevention in Li-Fraumeni syndrome (LFS) (2016) (0)
- A Methylation Density Binary Classifier for Predicting and Optimizing the Performance of Methylation Biomarkers in Clinical Samples (2019) (0)
- Abstract 1978: The poly-SUMO protein specific E3 ubiquitin ligase RNF4 is induced in multiple myeloma and reduces bortezomib-induced cell killing (2010) (0)
- Abstract AP13: NF-KAPPAB CLASSICAL VERSUS ALTERNATIVE PATHWAYS SUPPORT DISTINCT POPULATIONS OF OVARIAN CANCER TUMOR-INITIATING CELLS (2017) (0)
- From identification of therapeutic targets to clinical strategies (2016) (0)
- Mechanistic basis for synergy between SMAC-mimetic birinapant and chemotherapeutic agents: Insights for clinical development (2019) (0)
- Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth (2022) (0)
- Preface (2021) (0)
- Abstract 1754: A pharmacokinetics/pharmacodynamics study of sequence specificity of the PARP inhibitor, olaparib (O) with carboplatin (C) in recurrent women's cancers NCT01237067 (2012) (0)
- Abstract 4185: Targeting variant of CEACAM5 and CEACAM6 using NEO-201 and IL-15 in gynecologic cancers (2022) (0)
- Abstract LB-421: Dual shRNA technique to screen gene-to-gene interaction (2012) (0)
- Thanks to authors and peer reviewers (2007) (0)
- Abstract 619: ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NEO-201 against human carcinoma cells (2018) (0)
- Abstract B43: Characterization of ovarian cancer cells as in vivo models for preclinical studies. (2016) (0)
- Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune inhibition (2018) (0)
- Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial. (2023) (0)
- NF-κB Signaling Modulates miR-452-5p and miR-335-5p Expression to Functionally Decrease Epithelial Ovarian Cancer Progression in Tumor-Initiating Cells (2023) (0)
- Abstract 5727: Using ChIP-seq to identify genes regulated by RelA or RelB that support ovarian cancer tumor-initiating cell (TIC) characteristics (2022) (0)
This paper list is powered by the following services:
Other Resources About Christina Annunziata
What Schools Are Affiliated With Christina Annunziata?
Christina Annunziata is affiliated with the following schools:
